Highlights Foresee Pharmaceuticals Co., Ltd.

Equities

6576

TW0006576002

End-of-day quote Taipei Exchange Other stock markets 03:30:00 29/05/2024 am IST			5-day change	1st Jan Change
95.3 ^TWD	-0.63%		+1.17%	-0.94%

03/05	Foresee Pharmaceuticals Co., Ltd. announced that it expects to receive $7.841 million in funding	CI
30/04	Foresee Pharmaceuticals Announces First Subject Dosed in Its First-In-Human Clinical Trial of FP-020	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Foresee Pharmaceuticals Announces First Subject Dosed in Its First-In-Human Clinical Trial of FP-020	30/04	CI
Foresee Pharmaceuticals Receives Positive Recommendation from Data and Safety Monitoring Board to Continue the Casppian Study	01/04	CI
Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
Foresee Pharmaceuticals Co., Ltd. Obtains the Official Pharmaceutical License of CAMCEVI 42 Mg from the Ministry of Health and Welfare in Taiwan	01/12	CI
Foresee Pharmaceuticals Co., Ltd. Announces Last Patient Enrolled in the China Registration Clinical Trial of Leuprolide Injectable Emulsion in Prostate Cancer Has Completed Treatment	29/11	CI
Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11/11	CI
Foresee Pharmaceuticals Co., Ltd. Submits Phase 3 IND (Investigational New Drug) Application to China NMPA	16/23/16	CI
Foresee Pharmaceuticals Announces First Patient Dosed in the Casppian, Phase 3 Clinical Trial of Leuprolide (FP-001) Injectable Emulsion, 42 mg for the Treatment of Central Precocious Puberty Patients	13/23/13	CI
Foresee Pharmaceuticals to Present Phase 1/2 Fanconi Anemia Clinical Study Design for its ALDH2 Activator FP-045 at the Fanconi Anemia Research Fund 2023 Scientific Symposium	30/23/30	CI
Foresee Pharmaceuticals Announces FDA Orange Book Listing of New U.S. Patent for Camcevi®, Extending Patent Protection to 2039	29/23/29	CI
Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/23/14	CI
Foresee Pharmaceuticals to Present Allergic Asthma Study at European Medical Conference	26/23/26	MT
Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
Foresee Pharmaceuticals Co., Ltd. Announces the Primary Endpoint Data FP-025 in an Allergic Asthma Phase 2A Trial	04/23/04	CI
Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	24/23/24	CI
Foresee Pharmaceuticals Co., Ltd. Receives Approval from China NMPA for the Application of Phase 3 IND for FP-001 42 mg in Patients with Central Precocious Puberty	17/23/17	CI
Foresee Pharmaceuticals Co., Ltd. Receives Approval from Taiwan FDA for the Application of Phase 3 IND for FP-001 42 Mgin Patients with Central Precocious Puberty	02/23/02	CI
Foresee Pharmaceuticals Co., Ltd. Announces the Submission of A Phase 3 Clinical Trial Application for FP-001 42 Mg in Patients with Central Precocious Puberty to EMA	23/22/23	CI
Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/22/11	CI
Foresee Pharmaceuticals Co., Ltd. Announces Phase 3 Clinical Trial Application for Fp-00142 Mg in Patients with Central Precocious Puberty Has Been Accepted by China NMPA for Substantial Review	02/22/02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Foresee Pharmaceuticals Co., Ltd.

Equities

6576

TW0006576002

Highlights

Filters